Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021.
Liu J, Jayaram G, Varma T, Sammut S, Guerra C, Miller J. Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021. Journal Of Clinical Oncology 2023, 41: 1594-1594. DOI: 10.1200/jco.2023.41.16_suppl.1594.Peer-Reviewed Original ResearchPivotal trialsDrug approval packagesClinical trialsApproval packagesNovel cancer therapeuticsDemographic dataCancer therapeuticsUS cancer populationUS Cancer StatisticsCross-sectional studyOncology clinical trialsPercentage of participantsClinical trial infrastructurePercentage of trialsCancer populationProportion of trialsCancer statisticsDrug AdministrationOncology drugsTrial infrastructureCancer typesData reportingU.S. FoodOlder adultsTrials